We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
Read MoreHide Full Article
Shares of Conatus Pharmaceuticals Inc. plunged 50.8% in after-hours trading, after it announced disappointing top-line results from the phase IIb ENCORE-NF study.
Notably, shares of Conatus have plummeted 55.2% in the past six months compared with the industry’s decline of 4.7%.
Conatus is conducting three phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis (NASH). The programs are named ENCORE-NF (for NASH fibrosis), ENCORE-PH (for portal hypertension) and ENCORE-LF (for liver function).
The randomized, double-blind ENCORE-NF study was initiated in the first quarter of 2016 in patients with biopsy-confirmed NASH and liver fibrosis. The study enrolled and treated 318 patients with biopsy-confirmed NASH Clinical Research Network (CRN) fibrosis stages F1-F3 at baseline.
Patients enrolled in the study were randomized 1:1:1 to receive 5 mg of emricasan, 50 mg of emricasan, or placebo twice daily for 72 weeks. The trial was conducted at 87 U.S. and EU sites.
The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement without any worsening of steatohepatitis compared with placebo at week 72. However, the candidate did not meet its primary endpoint as it did not have the desired effect on these earlier-stage NASH fibrosis patients.
Nevertheless, the candidate is also being evaluated in more advanced-stage NASH cirrhosis patients. ENCORE-LF is evaluating emricasan in approximately 210 patients with decompensated NASH cirrhosis. The trial was initiated in the second quarter of 2017 and is advancing toward an event-driven analysis of clinical outcome results expected in mid-2019.
Conatus currently has a collaboration agreement with Swiss pharma giant, Novartis AG (NVS - Free Report) for the development of emricasan.
The failure of the study is disappointing, given the potential in the NASH market. In December 2018, the ENCORE-PH study also failed to meet the primary endpoint.
Earlier, biotech bigwig Gilead Sciences (GILD - Free Report) also announced the failure of a late-stage study on selonsertib, involving patients afflicted with compensated cirrhosis (F4) due to NASH.
Nevertheless, Intercept Pharmaceuticals, Inc. seems to be winning this race. The company announced positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH. Intercept stated that the primary endpoint of the study — fibrosis improvement without worsening of NASH at 18 months — was achieved with the 25 mg daily dose of OCA. The company plans to file for approval of OCA as a NASH treatment in the United States and Europe in the second half of 2019.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Conatus (CNAT) Declines on Failure of NASH Fibrosis Study
Shares of Conatus Pharmaceuticals Inc. plunged 50.8% in after-hours trading, after it announced disappointing top-line results from the phase IIb ENCORE-NF study.
Notably, shares of Conatus have plummeted 55.2% in the past six months compared with the industry’s decline of 4.7%.
Conatus is conducting three phase IIb ENCORE studies on emricasan for treating fibrosis or cirrhosis induced by nonalcoholic steatohepatitis (NASH). The programs are named ENCORE-NF (for NASH fibrosis), ENCORE-PH (for portal hypertension) and ENCORE-LF (for liver function).
The randomized, double-blind ENCORE-NF study was initiated in the first quarter of 2016 in patients with biopsy-confirmed NASH and liver fibrosis. The study enrolled and treated 318 patients with biopsy-confirmed NASH Clinical Research Network (CRN) fibrosis stages F1-F3 at baseline.
Patients enrolled in the study were randomized 1:1:1 to receive 5 mg of emricasan, 50 mg of emricasan, or placebo twice daily for 72 weeks. The trial was conducted at 87 U.S. and EU sites.
The trial’s primary endpoint was a ≥1 CRN fibrosis stage improvement without any worsening of steatohepatitis compared with placebo at week 72. However, the candidate did not meet its primary endpoint as it did not have the desired effect on these earlier-stage NASH fibrosis patients.
Nevertheless, the candidate is also being evaluated in more advanced-stage NASH cirrhosis patients. ENCORE-LF is evaluating emricasan in approximately 210 patients with decompensated NASH cirrhosis. The trial was initiated in the second quarter of 2017 and is advancing toward an event-driven analysis of clinical outcome results expected in mid-2019.
Conatus currently has a collaboration agreement with Swiss pharma giant, Novartis AG (NVS - Free Report) for the development of emricasan.
The failure of the study is disappointing, given the potential in the NASH market. In December 2018, the ENCORE-PH study also failed to meet the primary endpoint.
Earlier, biotech bigwig Gilead Sciences (GILD - Free Report) also announced the failure of a late-stage study on selonsertib, involving patients afflicted with compensated cirrhosis (F4) due to NASH.
Nevertheless, Intercept Pharmaceuticals, Inc. seems to be winning this race. The company announced positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH. Intercept stated that the primary endpoint of the study — fibrosis improvement without worsening of NASH at 18 months — was achieved with the 25 mg daily dose of OCA. The company plans to file for approval of OCA as a NASH treatment in the United States and Europe in the second half of 2019.
Zacks Rank
Conatus currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>